Oncotarget

Meta-Analysis:

Prognostic value of microRNAs in gastric cancer: a meta-analysis

Yue Zhang, Dong-Hui Guan, Rong-Xiu Bi, Jin Xie, Chuan-Hua Yang and Yue-Hua Jiang _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:55489-55510. https://doi.org/10.18632/oncotarget.18590

Metrics: PDF 9853 views  |   HTML 4878 views  |   ?  


Abstract

Yue Zhang1, Dong-Hui Guan2, Rong-Xiu Bi2, Jin Xie2, Chuan-Hua Yang3 and Yue-Hua Jiang4

1First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan 250355, Shandong, People’s Republic of China

2Department of Orthopedics, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, People’s Republic of China

3Department of Cardiology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, People’s Republic of China

4Central Laboratory, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, Shandong, People’s Republic of China

Correspondence to:

Yue-Hua Jiang, email: [email protected]

Keywords: microRNA, gastric cancer, prognosis, meta-analysis

Received: March 31, 2017     Accepted: May 08, 2017     Published: June 21, 2017

ABSTRACT

Background: Previous articles have reported that expression levels of microRNAs (miRNAs) are associated with survival time of patients with gastric cancer (GC). A systematic review and meta-analysis was performed to study the outcome of it.

Design: Meta-analysis.

Methods: English studies estimating expression levels of miRNAs with any of survival curves in GC were identified up till March 19, 2017 through performing online searches in PubMed, EMBASE, Web of Science and Cochrane Database of Systematic Reviews by two authors independently. The pooled hazard ratios (HR) with 95% confidence intervals (CI) were used to estimate the correlation between miRNA expression and overall survival (OS).

Results: Sixty-nine relevant articles about 26 miRNAs with 6148 patients were ultimately included. GC patients with high expression of miR-20b (HR=2.38, 95%CI=1.16-4.87), 21 (HR=1.77, 95%CI=1.01-3.08), 106b (HR=1.84, 95%CI=1.15-2.94), 196a (HR=2.66, 95%CI=1.94-3.63), 196b (HR=1.67, 95%CI=1.38-2.02), 214 (HR=1.84, 95%CI=1.27-2.67) or low expression of miR-125a (HR=2.06, 95%CI=1.26-3.37), 137 (HR=3.21, 95%CI=1.68-6.13), 141 (HR=2.47, 95%CI=1.34-4.56), 145 (HR=1.62, 95%CI=1.07-2.46), 146a (HR=2.60, 95%CI=1.63-4.13), 206 (HR=2.85, 95%CI=1.73-4.70), 218 (HR=2.61, 95%CI=1.74-3.92), 451 (HR=1.73, 95%CI=1.19-2.52), 486-5p (HR=2.45, 95%CI=1.65-3.65), 506 (HR=2.07, 95%CI=1.33-3.23) have significantly poor OS (P<0.05).

Conclusions: In summary, miR-20b, 21, 106b, 125a, 137, 141, 145, 146a, 196a, 196b, 206, 214, 218, 451, 486-5p and 506 demonstrate significantly prognostic value. Among them, miR-20b, 125a, 137, 141, 146a, 196a, 206, 218, 486-5p and 506 are strong biomarkers of prognosis in GC.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18590